Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

121. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. (Abstract)

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis.In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate (...) in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10).Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate.Lilly.Copyright © 2018 Elsevier Ltd. All rights reserved.

2017 Lancet Controlled trial quality: predicted high

122. Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis Full Text available with Trip Pro

Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis Osteoporosis is a common condition with serious consequences because of fractures. Despite availability of treatments to reduce fracture risk, there is a large osteoporosis treatment gap that has reached crisis proportions. There are too few specialists to provide services for patients who need them. Bone Health Extension for Community Health Care Outcomes (TeleECHO) is a strategy using real-time ongoing (...) -confidence in 20 domains of osteoporosis care showed substantial improvement with the ECHO intervention (P = 0.005). Bone Health TeleECHO can contribute to mitigating the crisis in osteoporosis care by leveraging scarce resources, providing motivated practitioners with skills to provide better skeletal health care, closer to home, with greater convenience, and lower cost than referral to a specialty center. Bone Health TeleECHO can be replicated in any location worldwide to reach anyone with Internet

2017 Journal of the Endocrine Society

123. Prevention of osteoporosis in female students based on the Orem self-care model Full Text available with Trip Pro

Prevention of osteoporosis in female students based on the Orem self-care model The World Health Organization has introduced osteoporosis as the fourth main enemy of mankind. Self care has served as a new trend in health care.Educational intervention for osteoporosis related preventive self care in female university students using the Orem model.This study is a controlled filed trial, carried out with female students of Islamic Azad University, Shahrekord Branch, Iran, from October 28, 2014 (...) to November 15, 2016. Two-stage random stratified sampling was performed and the data were collected through a validated questionnaire developed by the researcher for osteoporosis preventive self-care based on the Orem model. The intervention group received education about osteoporosis preventive self-care through two months training, as per the dimensions in the Orem model. For statistical analysis, independent-samples t-test and paired t-test were used in SPSS version 23.As revealed, mean scores

2017 Electronic physician

124. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Full Text available with Trip Pro

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption.We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate (...) observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed.In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed

2017 NEJM Controlled trial quality: uncertain

125. Bisphosphonates for treating osteoporosis

Bisphosphonates for treating osteoporosis Bisphosphonates for treating Bisphosphonates for treating osteoporosis osteoporosis T echnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1 Recommendations 4 2 The technologies 7 3 Committee discussion 9 Nature of the condition 9 Clinical management of the condition 9 Assessing

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

126. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Full Text available with Trip Pro

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP).We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group (...) GC users.Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D

2017 EvidenceUpdates

127. Osteoporosis. (Abstract)

Osteoporosis. Osteoporosis is a common systemic skeletal disorder resulting in bone fragility and increased fracture risk. However, management of osteoporosis and fracture prevention strategies are often not addressed by primary care clinicians, even in older patients with recent fractures. Evidence-based screening strategies will improve identification of patients who are most likely to benefit from drug treatment to prevent fracture. In addition, careful consideration of when pharmacotherapy

2017 Annals of Internal Medicine

128. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. (Abstract)

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with postmenopausal osteoporosis transitioning from (...) bisphosphonate therapy.This randomised, phase 3, open-label, active-controlled study was done at 46 sites in North America, Latin America, and Europe. We enrolled women (aged ≥55 to ≤90 years) with postmenopausal osteoporosis who had taken an oral bisphosphonate for at least 3 years before screening and alendronate the year before screening; an areal BMD T score of -2·5 or lower at the total hip, femoral neck, or lumbar spine; and a history of fracture. Patients were randomly assigned (1:1) via

2017 Lancet Controlled trial quality: predicted high

129. Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value

Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value ©Institute for Clinical and Economic Review, 2017 Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value Evidence Report June 16, 2017 Prepared for Note: When our process began, ICER expected FDA approval of two new anabolic agents for osteoporosis in the first half of 2017. On May 21, 2017, Amgen and UCB issued a press release with topline results from the ARCH trial (...) that include romosozumab. However, we have elected to retain the summary of the romosozumab trial results as well as the newly available summary results of the ARCH trial because they provide important contextual information to frame the larger discussion of the role of anabolic therapies in preventing osteoporotic fractures. ©Institute for Clinical and Economic Review, 2017 Page i Evidence Report – Anabolic Therapies for Osteoporosis ICER Staff and Consultants University of Washington School of Pharmacy

2017 California Technology Assessment Forum

130. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Full Text available with Trip Pro

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP).We conducted a systematic review to synthesize the evidence for the benefits and harms of GIOP prevention and treatment options. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence. We used a group (...) GC users.Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendations in this guideline are conditional (uncertain balance between benefits and harms). Recommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D

2017 EvidenceUpdates

131. Nutrition and osteoporosis prevention for the orthopaedic surgeon: A wholefoods approach Full Text available with Trip Pro

Nutrition and osteoporosis prevention for the orthopaedic surgeon: A wholefoods approach Osteoporosis is a prevalent and debilitating condition with no signs of subsiding. Rising numbers of people consuming nutrient-poor diets coupled with ageing populations and sedentary lifestyles appear to be the main drivers behind this.While the nutrients calcium and vitamin D have received most attention, there is growing evidence that wholefoods and other micronutrients have roles to play in primary (...) and potentially secondary osteoporosis prevention.Until recently, calcium and vitamin D were regarded as the main nutrients essential to bone health but now there are emerging roles for iron, copper and selenium, among others.Fruit and vegetables are still not being eaten in adequate amounts and yet contain micronutrients and phytochemicals useful for bone remodelling (bone formation and resorption) and are essential for reducing inflammation and oxidative stress.There is emerging evidence that dried fruits

2017 EFORT open reviews

132. Abaloparatide (Tymlos) Subcutaneous Injection - osteoporosis in postmenopausal women

Abaloparatide (Tymlos) Subcutaneous Injection - osteoporosis in postmenopausal women Tymlos Subcutaneous Injection U.S. Department of Health and Human Services Search FDA Submit search Tymlos Subcutaneous Injection DUPIXENT Company: Radius Health, Inc. Application No.: 208743 Approval Date: 04/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2017 FDA - Drug Approval Package

133. Bindex for people with suspected osteoporosis

Bindex for people with suspected osteoporosis Binde Bindex for in x for inv vestigating suspected osteoporosis estigating suspected osteoporosis Medtech innovation briefing Published: 31 May 2017 nice.org.uk/guidance/mib106 pathways Summary Summary The technology technology described in this briefing is Bindex, a portable pulse-echo ultrasound device used to help make decisions on the investigation and treatment of osteoporosis. The inno innovativ vative aspects e aspects are that it is pocket (...) sized and can be connected to and used with any laptop or desktop computer's USB socket. Unlike other quantitative ultrasound that measures sound speed and attenuation in the heel, Bindex makes measurements of the tibia applying thresholds of 90% sensitivity and specificity compared with axial dual-energy X-ray absorptiometry (DXA), to help with decisions on further tests and treatment for osteoporosis. The intended place in ther place in therap apy y would be to use Bindex alongside current

2017 National Institute for Health and Clinical Excellence - Advice

134. Romosozumab for osteoporosis in men

Romosozumab for osteoporosis in men Romosozumab for osteoporosis in men | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Romosozumab (...) for osteoporosis in men Romosozumab for osteoporosis in men May 2017 Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby increasing bone strength. The effectiveness and safety of romosozumab for the treatment of osteoporosis in men has been studied in a phase III clinical trial. The study

2017 NIHR Innovation Observatory

135. Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review. (Abstract)

Evidence-based prevention and treatment of osteoporosis after spinal cord injury: a systematic review. Spinal cord injury (SCI) results in accelerated bone mineral density (BMD) loss and disorganization of trabecular bone architecture. The mechanisms underlying post-SCI osteoporosis are complex and different from other types of osteoporosis. Findings of studies investigating efficacy of pharmacological or rehabilitative interventions in SCI-related osteoporosis are controversial. The aim (...) of this study was to review the literature pertaining to prevention and evidence-based treatments of SCI-related osteoporosis.In this systematic review, MEDLINE, EMBASE, PubMed, and the Cochrane Library were used to identify papers from 1946 to December 31, 2015. The search strategy involved the following keywords: spinal cord injury, osteoporosis, and bone loss.Finally, 56 studies were included according to the inclusion criteria. Only 16 randomized controlled trials (involving 368 patients) were found. We

2017 European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

136. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians. Full Text available with Trip Pro

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians. This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians.The ACP Clinical Guidelines Committee based these recommendations on a systematic review (...) and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence).ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence).ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence).ACP recommends against

2017 Annals of Internal Medicine

137. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. (Abstract)

Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Complications of chronic kidney disease (CKD) include weak bones and increased fracture risk.To review the benefits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with placebo, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in patients with CKD.PubMed and the Cochrane (...) Central Register of Controlled Trials from December 2006 through December 2016.Paired reviewers independently screened abstracts and full-text articles for English-language, randomized, controlled trials that had at least 6 months of follow-up; evaluated osteoporosis medications among patients with CKD; and reported on BMD, fractures, or safety (mortality and adverse events).Two reviewers serially abstracted data and independently assessed risk of bias and graded the strength of evidence (SOE

2017 Annals of Internal Medicine

138. Teriparatide (Movymia) - osteoporosis

Teriparatide (Movymia) - osteoporosis 10 November 2016 EMA/88527/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Movymia International non-proprietary name: teriparatide Procedure No. EMEA/H/C/004368/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 (...) authorisation to the European Medicines Agency (EMA) for Movymia, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The applicant applied for the following indication: Movymia is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated

2017 European Medicines Agency - EPARs

139. Answer to the Letter to the Editor of He Maolin et al. concerning "Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analy (Abstract)

Answer to the Letter to the Editor of He Maolin et al. concerning "Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analy 28168337 2018 04 02 2018 12 02 1432-0932 26 4 2017 04 European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society Eur Spine (...) J Answer to the Letter to the Editor of He Maolin et al. concerning "Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis" by Cheng X, Long HQ, Xu JH, et al. Eur Spine J (2016) 25: 3439. doi:10.1007/s00586-016-4395-6. 1322-1323 10.1007/s00586-017-4965-2 Cheng Xing X Department of Spine Surgery, The First Affiliated Hospital of Sun Yat-sen University

2017 European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

140. Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"

Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis" 1 Translation of Chapters 1 to 6 of the final report Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Empfehlungen für ein DMP Osteoporose (Version 1.0; Status: 1 April 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP “osteoporosis” 1 IQWiG Reports – V14-03 Extract of final report V14-03 Version 1.0 Guideline search and appraisal for a DMP “osteoporosis” 1 April 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Systematic guideline search and appraisal, as well as extraction of relevant

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)